Arca
Skip to content

Pulmonary arterial hypertension (pah)

Drug research and approvals for pulmonary arterial hypertension (pah): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 102 studies of pulmonary arterial hypertension (pah) are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, FDA has 21 approved and 49 open orphan designations naming it, and the EU has 15 authorised medicines for it.

  • Recruiting worldwide: 102
  • Trials authorized in Canada: 45
  • FDA orphan approvals: 21
  • EU medicines: 15

Recruiting Now

Newest start dates first, of 102 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 45; search them all in Canada trials
May 20, 2026A phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of once daily treprostinil…TREPROSTINIL (INS1009)InsmedPending
Mar 26, 2026An adaptive, 2-part randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ikt-001 in pulmonary arterial hypertensionIKT-001INHIBIKASE THERAPEUTICS, INC.Ongoing
Oct 24, 2025A phase 2b, randomized, double-blind, placebo-controlled trial of ikt-001 in pulmonary arterial hypertensionIKT-001INHIBIKASE THERAPEUTICS, INC.Closed
Sep 23, 2025A phase 2a, open-label, single arm multicenter exploratory study to evaluate the safety, tolerability, and efficacy of oral doses of roc-101 in patients with…ROC-101ALLROCK BIO, INC.Ongoing
Sep 18, 2025An open-label long-term follow-up study to evaluate the effects of sotatercept when added to background pulmonary arterial hypertension (pah) therapy for the…WINREVAIRMerck & Co. (MSD)Ongoing
Aug 7, 2025A phase 2, open-label extension study to investigate the safety and efficacy of pf-07868489 administered to adult participants with pulmonary arterial…PF-07868489PfizerClosed
Jul 29, 2025A phase lb, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study assessing the safety, pharmacokinetics, pharmacodynamies, and…HS23535PHARMA INC.Pending
Apr 29, 2025An open-label extension study to evaluate safety and tolerability of sotatercept (mk-7962) administered using a weight-banded approach in participants with…SOTATERCEPT (MK-7962)Merck & Co. (MSD)Pending
Nov 28, 2024A phase 1 / 2, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single…PF-07868489PfizerClosed
Sep 17, 2024A phase 2, multicenter, single-blinded, randomized study to evaluate the pharmacokinetics and safety of sotatercept (mk-7962) administered using either a…MK-7962 (SOTATERCEPT)Merck & Co. (MSD)Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 70
May 23, 2026Uptravitreatment of PAH (WHO Group I) in pediatric patients aged two years and older. Uptravi reduces NT-proBNP and is expected to delay disease…Actelion Pharmaceuticals LtdApproved
Oct 24, 2025Winrevairtreatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World…Merck Sharp & Dohme LLCApproved
Mar 26, 2024Winrevairtreatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity,…Merck Sharp & Dohme LLCApproved
Mar 22, 2024Opsynvichronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III)Actelion Pharmaceuticals US, Inc.Approved
Mar 3, 2023Revatiotreatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients (1 to 17 years old) to improve exercise ability and,…Viatris Specialty LLCApproved
Jan 31, 2023Revatiotreatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old to improve exercise ability and,…Viatris Specialty LLCApproved
May 23, 2022Tyvaso DPITreatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise abilityUnited Therapeutics CorporationApproved
Jul 29, 2021UptraviTreatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAHActelion Pharmaceuticals LtdApproved
Oct 18, 2019Remodulin;OrenitramOrenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve…United Therapeutics Corp.Approved
Sep 5, 2017TracleerTreatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital…Actelion Pharmaceuticals LtdApproved
Dec 21, 2015UptraviFor treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for…Actelion Pharmaceuticals LtdApproved
Dec 20, 2013Remodulin;OrenitramOrenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.United Therapeutics Corp.Approved
Oct 18, 2013OpsumitTreatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death,…Actelion Pharmaceuticals LtdApproved
Oct 8, 2013AdempasTreatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay…Bayer HealthCare Pharmaceuticals, Inc.Approved
Jul 30, 2009TyvasoTreatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distanceUnited Therapeutics CorporationApproved

Medicines Authorised in the EU

Newest first
Sep 24, 2025Macitentan Accordmacitentan · genericAccord HealthcareEMA ↗
Sep 24, 2025Macitentan AccordPharmamacitentan · genericAccord HealthcareEMA ↗
Sep 27, 2024Yuvancimacitentan;tadalafilJanssen-Cilag International NVEMA ↗
Aug 22, 2024Winrevairsotatercept · orphanMerck Sharp & Dohme B.V.EMA ↗
Jun 20, 2019Ambrisentan Viatris (previously Ambrisentan Mylan)ambrisentan · genericViatris LimitedEMA ↗
Jan 9, 2017Talmanco (previously Tadalafil Generics)tadalafil · genericViatris LimitedEMA ↗
Nov 14, 2016Granpidamsildenafil · genericAccord Healthcare S.L.U.EMA ↗
Sep 15, 2016Mysildecardsildenafil · genericViatris LimitedEMA ↗
May 12, 2016UptraviselexipagJanssen Cilag International NVEMA ↗
Dec 20, 2013OpsumitmacitentanEMA ↗
Jun 24, 2013Stayveerbosentan monohydrateJanssen-Cilag International NVEMA ↗
Oct 1, 2008Adcirca (previously Tadalafil Lilly)tadalafilEli Lilly Nederland B.V.EMA ↗
Apr 21, 2008VolibrisambrisentanGlaxoSmithKline Trading Services LimitedEMA ↗
Oct 28, 2005RevatiosildenafilViatris EESVEMA ↗
May 14, 2002TracleerbosentanEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.